Search results
Results from the WOW.Com Content Network
The FDA has banned Red Dye No. 3 dye from food and ingested drug products. Here are the food products containing Red 3 and how the ban affects you. ... as safe if it has been shown to cause cancer ...
The Food and Drug Administration (FDA) has banned a controversial red dye from food and ingested drugs that has been linked to cancer in animals. The FDA has decided to rescind its approval of FD ...
(The Center Square) – The U.S. Food and Drug Administration has revoked authorization for Red No. 3 in food and ingested drugs in response to a 2022 color additive petition. Safety concerns over ...
In April 2019, erdafitinib was granted approval by the US Food and Drug Administration (FDA) for treatment of metastatic or locally advanced bladder cancer with an FGFR3 or FGFR2 alteration that has progressed beyond traditional platinum-based therapies, subject to a confirmatory trial.
This list of over 500 monoclonal antibodies includes approved and investigational drugs as well as drugs that have been withdrawn from market; consequently, the column Use does not necessarily indicate clinical usage. See the list of FDA-approved therapeutic monoclonal antibodies in the monoclonal antibody therapy page.
The U.S. Food and Drug Administration (FDA) approved trastuzumab emtansine in February 2013, and granted the application for Kadcyla to Genentech. [18] The FDA granted the application for trastuzumab emtansine priority review and breakthrough therapy designations. [24] In 2013, trastuzumab emtansine was approved in the UK, [4] and the EU. [6]
The FDA cited in its announcement two studies that linked high levels of red dye No. 3 to cancer in male rats, but stressed that studies in other animals and humans did not show the same effect.
Crizotinib [2] and cabozantinib were the first to be approved by the U.S. FDA. Crizotinib received accelerated approval in 2011 for the treatment of patients with locally advanced or metastatic non-small cell lung cancer , while cabozantinib was approved in 2012 for the treatment of medullary thyroid cancer [ 3 ] and it has also started ...